Evidence map›Paper›PMID 39562336›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Morphological diversity in SDH-deficient renal carcinomas: a three-case exploration of variant features and dedifferentiation.

Fanni Sánta, Antranik Dabaghian, Boglárka Pósfai, Béla Vasas, László Kaizer, Alex Jenei, Bálint Scheich, Vanda Téglási, Zoltán Sápi, Krisztina Bíró and 8 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Fanni SántaDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Antranik DabaghianDepartment of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
Boglárka PósfaiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Béla VasasDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
László KaizerDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Alex JeneiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Bálint ScheichDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Vanda TéglásiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Zoltán SápiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Krisztina BíróDepartment of Medical Oncology and Clinical Pharmacology "C", National Institute of Oncology, Budapest, Hungary.
Anikó MarázDepartment of Oncotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Mavrogenis SteliosCenter for Urological Oncological Surgery, National Institute of Oncology, Budapest, Hungary.
Henriett ButzDepartment of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
Petr MartínekDepartment of Pathology, Faculty of Medicine in Pilsen, Charles University and Teaching Hospital, Pilsen, Czech Republic.
Kristýna PivovarčíkováDepartment of Pathology, Faculty of Medicine in Pilsen, Charles University and Teaching Hospital, Pilsen, Czech Republic.
Zsombor MeleghDepartment of Surgical and Molecular Pathology, Tumor Pathology Center, National Institute of Oncology, Ráth György Utca 7-9, Budapest, 1122, Hungary.
Mahmut AkgulDepartment of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
Levente KuthiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. kuthilevente@gmail.com.ORCID http://orcid.org/0000-0001-9247-6679

Funding

Magyarország Kormánya ÚNKP-23-2-SZTE-366Szent-Györgyi Albert Orvostudományi Kar, Szegedi Tudományegyetem 5S340A202
6 · The paper itself

Abstract

Succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC) is a rare subtype of renal neoplasm predominantly affecting younger individuals. It is characterized by germline mutations in SDHx genes, particularly type B. Histologically, SDH-deficient RCC features eosinophilic cytoplasmic cells forming solid nests or microcysts, sometimes entrapping normal tubules. We present three SDH-deficient RCC cases with overlapping morphological features with fumarate hydratase-deficient RCC and TFEB-rearranged RCC, an appearance that has not been previously described. All tumors lacked SDHB expression and harbored pathogenic SDHB mutations, with the germline nature confirmed in two cases. Metastasis developed in two patients. Our case set highlights the diagnostic challenges of molecularly defined renal tumors and expands the morphological spectrum of SDH-deficient RCC with unusual histological features. Clinically, these tumors appear to be aggressive.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsSuccinate DehydrogenaseAdultAgedBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorCell DedifferentiationFumarate HydrataseGerm-Line MutationHumansMaleMiddle AgedBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorFumarate HydrataseSDHB protein, humanSuccinate DehydrogenaseTFEB protein, humanRCCRenal cell carcinomaSDHBSuccinate dehydrogenase

Identifiers

PMID39562336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.